Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Specimen Handling 276pembrolizumab 227Magnetic Resonance Spectroscopy 226Carboplatin 180Cisplatin 166Biopsy 166Nivolumab 158Cyclophosphamide 144Radiotherapy 125Paclitaxel 124Gemcitabine 116Bevacizumab 95durvalumab 92Dexamethasone 88Rituximab 81Oxaliplatin 80venetoclax 75atezolizumab 71Fluorouracil 70Docetaxel 70Capecitabine 70Doxorubicin 68Etoposide 65Radiosurgery 64Ipilimumab 63Radiation 61Prednisone 60Cytarabine 60Lenalidomide 58Pemetrexed 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × methoxyamine × 90 days × Clear all
NCT05198830 2026-05-27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
42 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡